Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a phone app nudge people to exercise and slow Parkinson's before symptoms appear?

NCT ID NCT06993142

Prevention Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial tests whether a smartphone app can help 600 people with Parkinson's-related gene mutations increase their daily physical activity over two years. Participants set their own exercise goals and get feedback through the app. Researchers will measure changes in step counts and a composite score of early Parkinson's signs to see if more exercise might slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A motivational smartphone app that encourages increased physical activity volume and intensity over two years
What this could lead to
If it works, this could point toward a simple, drug-free way to slow or delay Parkinson's disease in people with genetic risk.
What could go wrong
The trial is early and exploratory, and the app may not succeed in boosting activity long-term. Also, the disease progression score is still being developed, so results may be unclear.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria 1. previously identified LRRK2 G2019S or GBA N370S variant based on genotyping 2. aged 50 years or older 3. able to understand the English language 4. being able to walk independently inside the home without the use of a walking aid 5. in possession of a suitable smartphone (screen size minimum 4.6 inch), (Android version 9 or iOS version 15 or newer) 6. Not in a high physical activity range during the 4-week eligibility and baseline period Exclusion criteria 1. clinically diagnosed or self-reported diagnosis neurodegenerative disease 2. self-reported falls of three or more per year 3. dexterity problems or cognitive impairments hampering smartphone use 4. if they are not aware of and do not wish to be informed about an increased risk of developing diseases associated with the LRRK2 or GBA1 risk variant 5. if individual is not community-dwelling 6. in possession of one of the following devices: Huawei P8 Lite; Huawei P9 Lite; Xiaomi Mi 6; Huawei P20 Lite (Fitbit is incompatible)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Basal ganglia diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal ganglia disorder brain disorder central nervous system disorder inherited disease susceptibility Motor Activity nervous system disorder neurodegenerative disease Parkinson disease parkinsonian disorder Prodromal Symptoms synucleinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Basal ganglia diseases Brain diseases Central nervous system diseases Cerebral disorder Genetic predisposition Nervous system diseases Neurodegenerative diseases Parkinson disease Parkinsonian disorders Prodromal stage Synucleinopathies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    2 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Radboud University Medical Center

    NOT_YET_RECRUITING

    Nijmegen, Gelderland, 6525 GA, Netherlands

    Contact Email: •••••@•••••

  • University of Rochester Center for Health and Technology (CHeT)

    RECRUITING

    Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.